3 days popular7 days popular1 month popular3 months popular

Pre-clinical study finds, with new approach, tumors shrink with little or no harm to normal cells

Researchers at Dana-Farber/’s Cancer and Blood Disorders Center have found a way to defeat one of the most tantalizing yet elusive target proteins in cancer cells – employing a strategy that turns the protein’s own molecular machinations against it.

[Rani George, MD, PhD, of Dana-Farber/Boston Children's Cancer and Blood Disorders Center, in her lab]
This is , MD, PhD, of Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, in her lab
Credit: Sam Ogden, Dana-Farber/Boston Children’s


The co-authors of the study are , PhD, Camilla Christensen, PhD, Tinghu Zhang, PhD, , , PhD, Caleb Yeung, , Kwok-Kin Wong, MD, PhD, Guo-Cheng Yuan, PhD, and Nathanael Gray, PhD, of Dana-Farber; Nicholas Kwiatkowski, PhD, Brian Abraham, PhD, and Richard Young, PhD, of the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology; and Antonio Perez-Atayde, PhD, of Boston Children’s Hospital.

The study was supported by grants from the National Institutes of Health, American Cancer Society, U.S. Department of Defense, and Friends for Life Neuroblastoma Foundation.

Dana-Farber Cancer Institute